Atle Fund Management AB Has $2.52 Million Stake in Autolus Therapeutics PLC Sponsored ADR $AUTL

Key Points

• Atle Fund Management AB increased its stake in Autolus Therapeutics PLC by 130.5%, owning approximately 1.1 million shares valued at $2.52 million as of its latest SEC filing.
• Autolus Therapeutics reported earnings of ($0.18) per share, exceeding analyst estimates and generating $13.50 million in revenue for the last quarter.
• Analysts have mixed views on Autolus, with one upgrading the stock to a "hold" rating and another maintaining a "buy" rating with a target price of $10.00.

Atle Fund Management AB lifted its stake in shares of Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL - Free Report) by 130.5% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,105,461 shares of the company's stock after purchasing an additional 625,817 shares during the period. Atle Fund Management AB owned approximately 0.42% of Autolus Therapeutics worth $2,520,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Armistice Capital LLC raised its position in Autolus Therapeutics by 19.6% in the 1st quarter. Armistice Capital LLC now owns 11,000,000 shares of the company's stock worth $17,050,000 after purchasing an additional 1,800,000 shares during the last quarter. Wellington Management Group LLP raised its position in shares of Autolus Therapeutics by 6.9% during the first quarter. Wellington Management Group LLP now owns 27,091,700 shares of the company's stock worth $41,992,000 after acquiring an additional 1,746,020 shares during the last quarter. Millennium Management LLC raised its position in shares of Autolus Therapeutics by 91.6% during the fourth quarter. Millennium Management LLC now owns 1,653,241 shares of the company's stock worth $3,885,000 after acquiring an additional 790,437 shares during the last quarter. Knott David M Jr acquired a new position in shares of Autolus Therapeutics during the first quarter valued at $651,000. Finally, Cetera Investment Advisers increased its position in Autolus Therapeutics by 169.9% in the fourth quarter. Cetera Investment Advisers now owns 356,222 shares of the company's stock worth $837,000 after purchasing an additional 224,222 shares during the period. Institutional investors and hedge funds own 72.83% of the company's stock.

Analyst Ratings Changes

A number of research analysts have issued reports on the stock. Wells Fargo & Company cut their target price on shares of Autolus Therapeutics from $6.00 to $5.00 and set an "overweight" rating on the stock in a research report on Wednesday, August 13th. Wall Street Zen raised shares of Autolus Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday, August 16th. Finally, Needham & Company LLC reaffirmed a "buy" rating and issued a $10.00 price objective on shares of Autolus Therapeutics in a research note on Monday, July 21st. Five analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the company presently has an average rating of "Buy" and an average price target of $9.12.

Autolus Therapeutics Price Performance

AUTL stock traded down $0.04 during trading hours on Tuesday, reaching $1.35. 1,647,332 shares of the stock were exchanged, compared to its average volume of 2,201,838. The firm's 50-day moving average is $1.91 and its 200-day moving average is $1.80. Autolus Therapeutics PLC Sponsored ADR has a 12 month low of $1.11 and a 12 month high of $5.00. The company has a market cap of $357.96 million, a price-to-earnings ratio of -1.60 and a beta of 1.87.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last posted its quarterly earnings data on Tuesday, August 12th. The company reported ($0.18) earnings per share for the quarter, topping the consensus estimate of ($0.24) by $0.06. The firm had revenue of $13.50 million for the quarter, compared to analyst estimates of $12.92 million. As a group, equities research analysts forecast that Autolus Therapeutics PLC Sponsored ADR will post -0.94 earnings per share for the current year.

Autolus Therapeutics Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.